Insulin Pump

The FDA has granted breakthrough device designation to an investigational bionic pancreas system, according to a press release from Beta Bionics.

Eli Lilly and Dexcom announced a global commercialization agreement to integrate DexCom’s continuous glucose monitoring devices into a personalized diabetes management system currently in development to advance the treatment of diabetes, according to a press release from the companies.

Diabetes devices such as sensors, insulin pumps and continuous glucose monitors continue to improve, offering people with diabetes more opportunities for connected care. As a result, adoption of these technologies is gradually rising. Approximately 30% to 40% of people with type 1 diabetes and an increasing number of people with insulin-dependent type 2 diabetes are using pump and sensor technology, according to a 2018 review published in Diabetes Care. Another recent study shows CGM can be cost-effective for adults with diabetes when compared with the daily use of test strips and improves overall blood glucose levels while reducing hypoglycemia.

The New England Journal of Medicine recently published a breakthrough study on the so-called artificial pancreas.

The FDA expanded the indication for insulin aspart injection 100 U/mL to include use in insulin infusion pumps for the improvement of glycemic response in adults with type 1 and type 2 diabetes, according to a press release from Novo Nordisk.

Children and adults with type 1 diabetes assigned to an artificial pancreas for 6 months spent an average of 2.6 fewer hours per day in hyperglycemia and 13 fewer minutes per day in hypoglycemia when compared with participants using sensor-augmented insulin pump therapy, according to findings published in The New England Journal of Medicine.

The FDA cleared Insult to market its tubeless Omnipod DASH Insulin Management System as an integrated insulin pump, allowing it to be part of an interoperable, automated insulin delivery system, according to an industry statement released Monday.

Abbott and Sanofi on Monday announced a partnership to develop new tools that will combine technology from Abbott’s FreeStyle Libre continuous glucose monitor with insulin dosing information for future Sanofi smart pens, insulin titration apps and cloud software, according to a press release from the companies.

Endocrine Today has compiled a list of recent news reports and interviews about diabetes technology.

HOUSTON — In this video exclusive, Gary Scheiner, MS, CDE, owner and clinical director, and Jennifer C. Smith, RD, LD, CDE, director of lifestyle and nutrition services, both at Integrated Diabetes Services in Wynnewood, Pennsylvania, speak with Endocrine Today Diabetes in Real Life columnist Susan Weiner, MS, RDN, CDE, CDN, FAADE, about how individuals with diabetes are taking more control of their devices through “hacking” and do-it-yourself measures.